This clinical study, published in October 2016, examines the positive effect of high dose intravenous vitamin C as an adjunct to post-operative pain management after laparoscopic cholecystectomy. It found that infusion of vitamin C (50mg/kg over 30 min) immediately after induction of anesthesia resulted in higher plasma concentrations of vitamin C at the completion of surgery and that it was associated with significantly reduced morphine consumption in the early post-operative period, along with significantly lower pain scores at rest during the first 24 hours after surgery.
Research on high-dose IV vitamin C and chemotherapy.

This research article, published in April 2015, discusses how biological and some clinical evidence suggest that high-dose intravenous vitamin C (IVC) could increase the effectiveness of cancer chemotherapy.
Read: High dose IVC and chemotherapy.

A case of regression of multiple pulmonary metastases after treatment with high-dose IV vitamin C.

This case report published by Yonsai Medical Journal in Korea describes the regression of multiple pulmonary metastases after treatment with high-dose vitamin C, which enabled a subsequent trial of TACE, eventually leading to complete remission of the primary hepatocellular carcinoma.
Read: High dose IVC and metastatic hepatocellular carcinoma.

This case study, published in 2016, documents the administration of supportive vitamin C therapy for cancer patients in Singapore. It concludes that IVC therapy, in combination with a diet and supplement regimen, is tolerated well, appears to have antitumor activity in some cases, does not impair the response of conventional therapy, is safe for most patients, and is inexpensive. It also concludes that IVC therapy has the potential to become an important chemotherapeutic method to combat cancer.
Read: High dose vitamin C and cancer in Singapore.

This very promising clinical study, published by the US National Library of Medicine National Institutes of Health is titled Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial.